---
document_datetime: 2025-12-02 05:05:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rezzayo.html
document_name: rezzayo.html
version: success
processing_time: 0.1239946
conversion_datetime: 2025-12-28 11:43:11.3723
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rezzayo

[RSS](/en/individual-human-medicine.xml/77411)

##### Authorised

This medicine is authorised for use in the European Union

rezafungin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rezzayo](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77360)
- [More information on Rezzayo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Rezzayo is an antifungal medicine used to treat adults with invasive candidiasis. Invasive candidiasis is a fungal infection caused by a yeast called Candida that has spread widely in the body and may also be present in the blood.

Invasive candidiasis is rare, and Rezzayo was designated an 'orphan medicine' (a medicine used in rare diseases) on 6 January 2021. Further information on the orphan designation can be found on the EMA website.

Rezzayo contains the active substance rezafungin.

Expand section

Collapse section

## How is Rezzayo used?

Rezzayo can only be obtained with a prescription and treatment should be started by a doctor experienced in the management of invasive fungal infections.

The medicine is given once a week as an infusion (drip) into a vein lasting at least 1 hour. The duration of treatment depends on how the patient responds, but should continue for at least 2 weeks after the last day that Candida is found in the patient's blood.

The medicine should be used according to official guidance issued at national level on the use of antifungal agents.

For more information about using Rezzayo, see the package leaflet or contact your doctor or pharmacist.

## How does Rezzayo work?

Rezafungin belongs to the group of antifungal medicines called echinocandins. It works by interfering with the production of a molecule called (1,3)-β-D-glucan, which strengthens the fungal cell wall. Treatment with rezafungin makes Candida cells fragile, causing them to die. This helps to bring invasive candidiasis under control and reduces damage from the disease.

## What benefits of Rezzayo have been shown in studies?

A main study involving 187 people with invasive candidiasis showed that Rezzayo was as effective as caspofungin (another antifungal medicine) in the treatment of invasive candidiasis. After 14 days of treatment, 59% (55 out of 93) of people who received Rezzayo had no signs or symptoms of Candida infection compared with 61% (57 out of 94) of those who received caspofungin.

Additional data showed that the rate of death due to any cause after 30 days of treatment was 24% (22 out of 93) for people treated with Rezzayo compared with 21% (20 out of 94) for those treated with caspofungin.

## What are the risks associated with Rezzayo?

For the full list of side effects and restrictions with Rezzayo, see the package leaflet.

The most common side effects with Rezzayo (which may affect more than 1 in 10 people) include hypokalaemia (low blood potassium levels), fever and diarrhoea.

Rezzayo must not be used by people who are hypersensitive (allergic) to other echinocandin medicines or to any of the ingredients of Rezzayo (which are listed in the package leaflet).

## Why is Rezzayo authorised in the EU?

Rezzayo has been found to be as effective in treating invasive candidiasis as an authorised antifungal medicine of the same class, caspofungin. Although there was some uncertainty regarding the effectiveness of the medicine compared with that of caspofungin due to the relatively small number of patients in the study, additional data supported the main study outcome. In addition, Rezzayo is given once a week compared with once a day for other medicines of the same class. The safety profile of the medicine is in line with that of other medicines of the same class. The European Medicines Agency therefore decided that Rezzayo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Rezzayo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rezzayo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Rezzayo are continuously monitored. Suspected side effects reported with Rezzayo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Rezzayo

Rezzayo received a marketing authorisation valid throughout the EU on 22 December 2023.

Rezzayo: EPAR - Medicine overview

Reference Number: EMEA/H/C/5900

English (EN) (125.91 KB - PDF)

**First published:** 24/01/2024

[View](/en/documents/overview/rezzayo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-133)

български (BG) (119.29 KB - PDF)

**First published:**

24/01/2024

[View](/bg/documents/overview/rezzayo-epar-medicine-overview_bg.pdf)

español (ES) (104.12 KB - PDF)

**First published:**

24/01/2024

[View](/es/documents/overview/rezzayo-epar-medicine-overview_es.pdf)

čeština (CS) (114.97 KB - PDF)

**First published:**

24/01/2024

[View](/cs/documents/overview/rezzayo-epar-medicine-overview_cs.pdf)

dansk (DA) (103.13 KB - PDF)

**First published:**

24/01/2024

[View](/da/documents/overview/rezzayo-epar-medicine-overview_da.pdf)

Deutsch (DE) (104.01 KB - PDF)

**First published:**

24/01/2024

[View](/de/documents/overview/rezzayo-epar-medicine-overview_de.pdf)

eesti keel (ET) (102.83 KB - PDF)

**First published:**

24/01/2024

[View](/et/documents/overview/rezzayo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (126.34 KB - PDF)

**First published:**

24/01/2024

[View](/el/documents/overview/rezzayo-epar-medicine-overview_el.pdf)

français (FR) (104.24 KB - PDF)

**First published:**

24/01/2024

[View](/fr/documents/overview/rezzayo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (110.29 KB - PDF)

**First published:**

24/01/2024

[View](/hr/documents/overview/rezzayo-epar-medicine-overview_hr.pdf)

italiano (IT) (103.8 KB - PDF)

**First published:**

24/01/2024

[View](/it/documents/overview/rezzayo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (123.6 KB - PDF)

**First published:**

24/01/2024

[View](/lv/documents/overview/rezzayo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (114.34 KB - PDF)

**First published:**

24/01/2024

[View](/lt/documents/overview/rezzayo-epar-medicine-overview_lt.pdf)

magyar (HU) (110.63 KB - PDF)

**First published:**

24/01/2024

[View](/hu/documents/overview/rezzayo-epar-medicine-overview_hu.pdf)

Malti (MT) (115.77 KB - PDF)

**First published:**

24/01/2024

[View](/mt/documents/overview/rezzayo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (104.09 KB - PDF)

**First published:**

24/01/2024

[View](/nl/documents/overview/rezzayo-epar-medicine-overview_nl.pdf)

polski (PL) (115.15 KB - PDF)

**First published:**

24/01/2024

[View](/pl/documents/overview/rezzayo-epar-medicine-overview_pl.pdf)

português (PT) (103.67 KB - PDF)

**First published:**

24/01/2024

[View](/pt/documents/overview/rezzayo-epar-medicine-overview_pt.pdf)

română (RO) (112.09 KB - PDF)

**First published:**

24/01/2024

[View](/ro/documents/overview/rezzayo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (113.74 KB - PDF)

**First published:**

24/01/2024

[View](/sk/documents/overview/rezzayo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (109.5 KB - PDF)

**First published:**

24/01/2024

[View](/sl/documents/overview/rezzayo-epar-medicine-overview_sl.pdf)

Suomi (FI) (103.45 KB - PDF)

**First published:**

24/01/2024

[View](/fi/documents/overview/rezzayo-epar-medicine-overview_fi.pdf)

svenska (SV) (103.11 KB - PDF)

**First published:**

24/01/2024

[View](/sv/documents/overview/rezzayo-epar-medicine-overview_sv.pdf)

Rezzayo : EPAR - Risk-management-plan summary

English (EN) (784.04 KB - PDF)

**First published:** 24/01/2024

[View](/en/documents/rmp-summary/rezzayo-epar-risk-management-plan-summary_en.pdf)

## Product information

Rezzayo : EPAR - Product information

English (EN) (259.68 KB - PDF)

**First published:** 24/01/2024

**Last updated:** 18/06/2025

[View](/en/documents/product-information/rezzayo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-981)

български (BG) (300.83 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/bg/documents/product-information/rezzayo-epar-product-information_bg.pdf)

español (ES) (209.93 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/es/documents/product-information/rezzayo-epar-product-information_es.pdf)

čeština (CS) (302.24 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/cs/documents/product-information/rezzayo-epar-product-information_cs.pdf)

dansk (DA) (214.14 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/da/documents/product-information/rezzayo-epar-product-information_da.pdf)

Deutsch (DE) (235.51 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/de/documents/product-information/rezzayo-epar-product-information_de.pdf)

eesti keel (ET) (188.59 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/et/documents/product-information/rezzayo-epar-product-information_et.pdf)

ελληνικά (EL) (323.24 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/el/documents/product-information/rezzayo-epar-product-information_el.pdf)

français (FR) (224.15 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/fr/documents/product-information/rezzayo-epar-product-information_fr.pdf)

hrvatski (HR) (273.94 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/hr/documents/product-information/rezzayo-epar-product-information_hr.pdf)

íslenska (IS) (337.85 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/is/documents/product-information/rezzayo-epar-product-information_is.pdf)

italiano (IT) (196.69 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/it/documents/product-information/rezzayo-epar-product-information_it.pdf)

latviešu valoda (LV) (275.12 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/lv/documents/product-information/rezzayo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (271.46 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/lt/documents/product-information/rezzayo-epar-product-information_lt.pdf)

magyar (HU) (285.32 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/hu/documents/product-information/rezzayo-epar-product-information_hu.pdf)

Malti (MT) (289.49 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/mt/documents/product-information/rezzayo-epar-product-information_mt.pdf)

Nederlands (NL) (207.36 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/nl/documents/product-information/rezzayo-epar-product-information_nl.pdf)

norsk (NO) (221.03 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/no/documents/product-information/rezzayo-epar-product-information_no.pdf)

polski (PL) (288.28 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/pl/documents/product-information/rezzayo-epar-product-information_pl.pdf)

português (PT) (314.75 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/pt/documents/product-information/rezzayo-epar-product-information_pt.pdf)

română (RO) (269.5 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/ro/documents/product-information/rezzayo-epar-product-information_ro.pdf)

slovenčina (SK) (278.82 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/sk/documents/product-information/rezzayo-epar-product-information_sk.pdf)

slovenščina (SL) (264.55 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/sl/documents/product-information/rezzayo-epar-product-information_sl.pdf)

Suomi (FI) (201.38 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/fi/documents/product-information/rezzayo-epar-product-information_fi.pdf)

svenska (SV) (208.4 KB - PDF)

**First published:**

24/01/2024

**Last updated:**

18/06/2025

[View](/sv/documents/product-information/rezzayo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0007 27/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rezzayo : EPAR - All Authorised Presentations

English (EN) (40.22 KB - PDF)

**First published:** 24/01/2024

[View](/en/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-731)

български (BG) (47.07 KB - PDF)

**First published:**

24/01/2024

[View](/bg/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_bg.pdf)

español (ES) (39.61 KB - PDF)

**First published:**

24/01/2024

[View](/es/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (49 KB - PDF)

**First published:**

24/01/2024

[View](/cs/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (41.18 KB - PDF)

**First published:**

24/01/2024

[View](/da/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (41.5 KB - PDF)

**First published:**

24/01/2024

[View](/de/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (37.57 KB - PDF)

**First published:**

24/01/2024

[View](/et/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (53.68 KB - PDF)

**First published:**

24/01/2024

[View](/el/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_el.pdf)

français (FR) (37.87 KB - PDF)

**First published:**

24/01/2024

[View](/fr/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (56.78 KB - PDF)

**First published:**

24/01/2024

[View](/hr/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (40.63 KB - PDF)

**First published:**

24/01/2024

[View](/is/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (37.63 KB - PDF)

**First published:**

24/01/2024

[View](/it/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (55.75 KB - PDF)

**First published:**

24/01/2024

[View](/lv/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (56.06 KB - PDF)

**First published:**

24/01/2024

[View](/lt/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (48.63 KB - PDF)

**First published:**

24/01/2024

[View](/hu/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (57 KB - PDF)

**First published:**

24/01/2024

[View](/mt/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (37.96 KB - PDF)

**First published:**

24/01/2024

[View](/nl/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (41.34 KB - PDF)

**First published:**

24/01/2024

[View](/no/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_no.pdf)

polski (PL) (58.34 KB - PDF)

**First published:**

24/01/2024

[View](/pl/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_pl.pdf)

português (PT) (40.92 KB - PDF)

**First published:**

24/01/2024

[View](/pt/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_pt.pdf)

română (RO) (55.9 KB - PDF)

**First published:**

24/01/2024

[View](/ro/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (57.18 KB - PDF)

**First published:**

24/01/2024

[View](/sk/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (48.27 KB - PDF)

**First published:**

24/01/2024

[View](/sl/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (39.15 KB - PDF)

**First published:**

24/01/2024

[View](/fi/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (37.44 KB - PDF)

**First published:**

24/01/2024

[View](/sv/documents/all-authorised-presentations/rezzayo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rezzayo Active substance rezafungin International non-proprietary name (INN) or common name rezafungin Therapeutic area (MeSH)

- Candidiasis
- Candidiasis, Invasive

Anatomical therapeutic chemical (ATC) code J02AX08

### Pharmacotherapeutic group

Antimycotics for systemic use

### Therapeutic indication

Rezzayo is indicated for the treatment of invasive candidiasis in adults.

Consideration should be given to official guidance on the appropriate use of antifungal agents.

## Authorisation details

EMA product number EMEA/H/C/005900

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Mundipharma GmbH

De-Saint-Exupery-Straße 10 Flughafen 60549 Frankfurt Am Main GERMANY

Opinion adopted 12/10/2023 Marketing authorisation issued 22/12/2023 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rezzayo : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (150.7 KB - PDF)

**First published:** 18/06/2025

[View](/en/documents/procedural-steps-after/rezzayo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Rezzayo-PAM-0000266096 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2064733

English (EN) (307.28 KB - PDF)

**First published:** 11/09/2025

[View](/en/documents/variation-report/rezzayo-pam-0000266096-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Rezzayo : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/487522/2023

English (EN) (8.46 MB - PDF)

**First published:** 24/01/2024

[View](/en/documents/assessment-report/rezzayo-epar-public-assessment-report_en.pdf)

Rezzayo : Orphan maintenance assessment report

English (EN) (416.31 KB - PDF)

**First published:** 24/01/2024

[View](/en/documents/orphan-maintenance-report/rezzayo-orphan-maintenance-assessment-report_en.pdf)

CHMP summary of positive opinion for Rezzayo

Adopted

Reference Number: EMA/448724/2023

English (EN) (101.92 KB - PDF)

**First published:** 13/10/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-rezzayo_en.pdf)

#### News on Rezzayo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023) 13/10/2023

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Rezzayo : EPAR - Product information - tracked changes

English (EN) (127.92 KB - DOCX)

**First published:** 18/06/2025

[View](/en/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-755)

български (BG) (124.66 KB - DOCX)

**First published:**

18/06/2025

[View](/bg/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_bg.docx)

español (ES) (124.8 KB - DOCX)

**First published:**

18/06/2025

[View](/es/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_es.docx)

čeština (CS) (128.04 KB - DOCX)

**First published:**

18/06/2025

[View](/cs/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (120.59 KB - DOCX)

**First published:**

18/06/2025

[View](/da/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (127.67 KB - DOCX)

**First published:**

18/06/2025

[View](/de/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (113.88 KB - DOCX)

**First published:**

18/06/2025

[View](/et/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (128.21 KB - DOCX)

**First published:**

18/06/2025

[View](/el/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_el.docx)

français (FR) (119.83 KB - DOCX)

**First published:**

18/06/2025

[View](/fr/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (119.45 KB - DOCX)

**First published:**

18/06/2025

[View](/hr/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (121.04 KB - DOCX)

**First published:**

18/06/2025

[View](/is/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_is.docx)

italiano (IT) (118.71 KB - DOCX)

**First published:**

18/06/2025

[View](/it/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (138.1 KB - DOCX)

**First published:**

18/06/2025

[View](/lv/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (116.84 KB - DOCX)

**First published:**

18/06/2025

[View](/lt/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (118.72 KB - DOCX)

**First published:**

18/06/2025

[View](/hu/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (121.94 KB - DOCX)

**First published:**

18/06/2025

[View](/mt/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (118.72 KB - DOCX)

**First published:**

18/06/2025

[View](/nl/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (122.49 KB - DOCX)

**First published:**

18/06/2025

[View](/no/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_no.docx)

polski (PL) (122.58 KB - DOCX)

**First published:**

18/06/2025

[View](/pl/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_pl.docx)

português (PT) (91.02 KB - DOCX)

**First published:**

18/06/2025

[View](/pt/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_pt.docx)

română (RO) (113.08 KB - DOCX)

**First published:**

18/06/2025

[View](/ro/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (121.13 KB - DOCX)

**First published:**

18/06/2025

[View](/sk/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (114.04 KB - DOCX)

**First published:**

18/06/2025

[View](/sl/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (142.81 KB - DOCX)

**First published:**

18/06/2025

[View](/fi/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (73.28 KB - DOCX)

**First published:**

18/06/2025

[View](/sv/documents/product-information-tracked-changes/rezzayo-epar-product-information-tracked-changes_sv.docx)

#### More information on Rezzayo

- [EMEA-002319-PIP01-17-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002319-pip01-17-m03)
- [EU/3/20/2385 - orphan designation for treatment of invasive candidiasis](/en/medicines/human/orphan-designations/eu-3-20-2385)

**This page was last updated on** 11/09/2025

## Share this page

[Back to top](#main-content)